Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Fax: 617 926 5050

Website: eyepointpharma.com

Address:

480 Pleasant Street, Suite A-210, Watertown, United States

rizzato Nov. 14 at 3:52 PM

$EYPT thanks mizuho please show us your power and bring us again to 15 at least

0 · Reply

rizzato Nov. 14 at 7:17 AM

$EYPT mizuho did you notice we were down 4% yesterday , ready to buy today ?hurry up

0 · Reply

rizzato Nov. 13 at 6:20 PM

$EYPT probably mizuho forgot to add more shares today so please mizuho walk up and start to add more so that we can go up again and not see that fuck........ red line

0 · Reply

rizzato Nov. 13 at 3:10 PM

$EYPT is there anyone who could explain me why we are -5% with 0 volume?

0 · Reply

rizzato Nov. 13 at 2:57 PM

$EYPT why?

0 · Reply

Poet5 Nov. 12 at 5:52 PM

$EYPT This is now making a run to 15-20 range quite steadily and easily quicker than you can imagine.

0 · Reply

KimboIce Nov. 12 at 5:09 PM

$EYPT listened to the Stifel fireside chat . Dr. Duker was on his A game . Clearly differentiated Voronalib’s advantages in TKI space .

0 · Reply

Harpua_dumphuk Nov. 12 at 4:33 PM

$EYPT I just love this stock! You can buy it below the offer price and watch it pop hard. Tons of support and you buy any weakness. You know they are issuing enough stock to let a big player into it. Super bullish.

3 · Reply

rizzato Nov. 12 at 4:24 PM

$EYPT hei Mizuho thanks now I need the price again at least at 15usd soon

0 · Reply

rizzato Nov. 12 at 4:01 PM

$EYPT EyePoint selloff brings buying opportunity, says Mizuho hei Mizuho please start to buy more shares because we need to go up and not down hahahahahah

0 · Reply

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 9 days ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Nov 3, 2025, 7:00 AM EST - 11 days ago

EyePoint Announces Participation at Upcoming Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 16 days ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 16, 2025, 7:00 AM EDT - 4 weeks ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 15, 2025, 11:01 AM EDT - 4 weeks ago

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

Oct 14, 2025, 10:43 PM EDT - 4 weeks ago

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 4:35 PM EDT - 4 weeks ago

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:01 PM EDT - 4 weeks ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Sep 2, 2025, 6:03 PM EDT - 2 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 6, 2025, 4:09 PM EDT - 3 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 3 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:00 AM EDT - 3 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Jul 30, 2025, 7:00 AM EDT - 3 months ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 29, 2025, 7:00 AM EDT - 3 months ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jun 12, 2025, 11:03 AM EDT - 5 months ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

May 27, 2025, 7:00 AM EDT - 6 months ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 16, 2025, 7:00 AM EDT - 6 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 7, 2025, 2:49 PM EDT - 6 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 6 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 7 months ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 27, 2025, 7:00 AM EDT - 8 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 5, 2025, 2:51 PM EST - 9 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:00 AM EST - 9 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Feb 26, 2025, 7:00 AM EST - 9 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 25, 2025, 7:00 AM EST - 9 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:39 PM EST - 10 months ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 7:00 AM EST - 10 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 8, 2025, 7:00 AM EST - 11 months ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 14, 2024, 5:04 AM EST - 1 year ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 29, 2024, 5:35 PM EDT - 1 year ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024, 12:50 PM EDT - 1 year ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 6, 2024, 9:10 AM EDT - 1 year ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 2, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 7, 2024, 12:29 PM EST - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

rizzato Nov. 14 at 3:52 PM

$EYPT thanks mizuho please show us your power and bring us again to 15 at least

0 · Reply

rizzato Nov. 14 at 7:17 AM

$EYPT mizuho did you notice we were down 4% yesterday , ready to buy today ?hurry up

0 · Reply

rizzato Nov. 13 at 6:20 PM

$EYPT probably mizuho forgot to add more shares today so please mizuho walk up and start to add more so that we can go up again and not see that fuck........ red line

0 · Reply

rizzato Nov. 13 at 3:10 PM

$EYPT is there anyone who could explain me why we are -5% with 0 volume?

0 · Reply

rizzato Nov. 13 at 2:57 PM

$EYPT why?

0 · Reply

Poet5 Nov. 12 at 5:52 PM

$EYPT This is now making a run to 15-20 range quite steadily and easily quicker than you can imagine.

0 · Reply

KimboIce Nov. 12 at 5:09 PM

$EYPT listened to the Stifel fireside chat . Dr. Duker was on his A game . Clearly differentiated Voronalib’s advantages in TKI space .

0 · Reply

Harpua_dumphuk Nov. 12 at 4:33 PM

3 · Reply

rizzato Nov. 12 at 4:24 PM

$EYPT hei Mizuho thanks now I need the price again at least at 15usd soon

0 · Reply

rizzato Nov. 12 at 4:01 PM

$EYPT EyePoint selloff brings buying opportunity, says Mizuho hei Mizuho please start to buy more shares because we need to go up and not down hahahahahah

0 · Reply

rizzato Nov. 11 at 9:01 PM

$EYPT they doesn't want the price to go up

0 · Reply

rizzato Nov. 11 at 3:41 PM

$EYPT 0 VOLUME TODAY

0 · Reply

rizzato Nov. 11 at 2:45 PM

$EYPT https://www.theglobeandmail.com/investing/markets/stocks/EYPT-Q/pressreleases/32530217/eyepoint-pharmaceuticals-files-200m-stock-offering-prospectus/

0 · Reply

rizzato Nov. 10 at 5:50 PM

$EYPT https://stockscan.io/stocks/EYPT/forecast

0 · Reply

rizzato Nov. 10 at 5:43 PM

$EYPT 5 days and we should know who has added more share recently

0 · Reply

rizzato Nov. 10 at 5:30 PM

$EYPT 172 million at 12 capital raise it doesn't justify the actual share price . we should go up soon

0 · Reply

rizzato Nov. 10 at 3:21 PM

$EYPT https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-eyepoint-pharmaceuticals-eypt-blurbs?mod=mw_quote_news

0 · Reply

rizzato Nov. 8 at 6:43 AM

$EYPT as already said price totally controlled by them

0 · Reply

rizzato Nov. 7 at 9:06 PM

$EYPT is there someone who could confirm me that the volume moved from 1100k to 1500k in the last 5 minutes?

0 · Reply

rizzato Nov. 7 at 3:06 PM

$EYPT in about a week we will have the updated list of the main shareholder and could be we will understand a little bit more the situation who added the shares of 170 million and some more

0 · Reply

rizzato Nov. 7 at 2:24 PM

$EYPT who is still playing with us?

0 · Reply

Momo7002momo Nov. 7 at 7:36 AM

$EYPT bullish keep eye on $CYN breaking out soon read the charts!

0 · Reply

Market Cap	952.88M
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	1,126,100
Avg Vol	1,312,838
Day's Range	N/A - N/A
Shares Out	82.79M
Stochastic %K	58%
Beta	1.85
Analysts	Strong Sell
Price Target	$34.00